Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
24.69
+0.47 (1.94%)
Nov 22, 2024, 4:00 PM EST - Market closed
Denali Therapeutics Employees
Denali Therapeutics had 445 employees as of December 31, 2023. The number of employees increased by 18 or 4.22% compared to the previous year.
Employees
445
Change (1Y)
18
Growth (1Y)
4.22%
Revenue / Employee
n/a
Profits / Employee
-$960,658
Market Cap
3.55B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
BrightSpring Health Services | 35,000 |
Acadia Healthcare Company | 23,500 |
DENTSPLY SIRONA | 15,000 |
Envista Holdings | 12,800 |
Perrigo Company | 9,140 |
Option Care Health | 7,802 |
PTC Therapeutics | 1,055 |
Apellis Pharmaceuticals | 706 |
DNLI News
- 7 days ago - Denali Has A Neurodegenerative Edge Despite Market Skepticism - Seeking Alpha
- 17 days ago - Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights - GlobeNewsWire
- 2 months ago - Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome) - GlobeNewsWire
- 3 months ago - Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology - Seeking Alpha
- 3 months ago - Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous Administration - GlobeNewsWire
- 4 months ago - Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights - GlobeNewsWire
- 6 months ago - Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies - GlobeNewsWire
- 6 months ago - Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data - Seeking Alpha